Skip to main content
    U

    United Therapeutics Corporation (UTHR)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $584.10
    -3.78 (-0.64%)

    Market Cap: $25.04B

    Last updated: Nov 17, 2026 at 4:33 PM ET

    United Therapeutics Corporation (UTHR) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    United Therapeutics (UTHR) has a market cap of $25.04B and an enterprise value of $23.85B. Its trailing P/E of 22.0x is above its 10-year median of 12.4x. It kept 38.61% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 4.75% below the market cap, as cash exceeds debt.

    Market Cap$25.04B
    Enterprise Value$23.85B
    Latest price (Nov 17, 2026)$584.10

    Key Dates

    The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 23, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.23% in the quarter ended Sep 30, 2026 and shrank 2.15% a year over 2 years.

    Shares Outstanding42.70M
    Shares Change (YoY)-2.51%
    Shares Change (QoQ)+0.23%
    Share Count Growth (2Y CAGR)-2.15%

    Valuation Ratios

    Sales and book value multiples are 7.8x and 4.0x. Its year-end P/E ranged from 8.9x to 17.5x from 2016 to 2025.

    P/E Ratio22.0x
    Forward P/E21.8x
    P/S Ratio7.8x
    Forward P/S7.7x
    P/B Ratio4.0x
    P/TBV Ratio4.0x
    P/FCF Ratio28.8x
    P/OCF Ratio17.5x
    PEG Ratio1.6

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 16.2x EBITDA and 27.4x free cash flow.

    EV / Earnings19.4x
    EV / Sales7.5x
    EV / EBITDA16.2x
    EV / FCF27.4x

    Price Statistics

    The stock is up 25.24% over 52 weeks and trades 6.91% above its 50-day average.

    Beta (1Y)0.43
    52-Week Change+25.24%
    1-Month Change+7.54%
    3-Month Change+10.39%
    6-Month Change+3.05%
    5-Year Change+213.86%
    10-Year Change+398.64%
    Total Return (1Y)+25.24%
    Total Return (3Y CAGR)+36.63%
    Total Return (5Y CAGR)+23.60%
    Return vs SPY (1Y)+11.00%
    Max Drawdown (1Y)-20.87%
    Max Drawdown (3Y)-33.00%
    Sharpe Ratio (1Y)0.60
    Correlation with SPY (1Y)0.17
    50-Day Average$546.33
    200-Day Average$538.59
    52-Week Range$455.63 to $614.23
    RSI (14 Days)54.5
    Average Volume (20 Days)522.66K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.61x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio4.61x
    Quick Ratio4.29x
    Debt / Equity0.00x
    Interest Coverage115.08x

    Returns and Efficiency

    Return on equity is 19.61% over the last 12 months, against a 5-year average of 16.20%.

    Return on Equity (ROE)19.61%
    Return on Assets (ROA)17.50%
    ROE (5Y Average)16.20%
    ROA (5Y Average)13.63%
    ROIC (5Y Average)14.42%
    Asset Turnover0.44x
    Inventory Turnover2.20x
    Receivables Turnover9.68x
    Cash Conversion Cycle-223 days

    Taxes

    Income tax took 18.37% of pretax income over the last 12 months.

    Income Tax (TTM)$277.00M
    Effective Tax Rate18.37%

    Scores

    UTHR has an Altman Z-Score of 23.10, in the safe zone above 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.

    Altman Z-Score23.10
    Altman Z ZoneSafe
    Piotroski F-Score7 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $3.19B over the last 12 months is up 1.89% from the 12 months before.

    Revenue$3.19B
    Revenue Growth (YoY)+1.89%
    Gross Profit$2.75B
    Operating Income$1.32B
    Pretax Income$1.51B
    Net Income$1.23B
    Reported EPS (TTM)$26.50

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 89.33% of the $7.03B in total assets.

    Cash and Equivalents$1.19B
    Total Debt$0
    Net Cash$1.19B
    Net Cash Per Share$27.84
    Working Capital$2.26B
    Shareholder Equity$6.28B
    Book Value Per Share$146.98
    Tangible Book Value$6.16B
    Tangible Book Per Share$144.30
    Total Assets$7.03B
    Total Liabilities$758.10M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $562.40M of capital spending, operating cash flow left $867.20M of free cash flow.

    Operating Cash Flow$1.43B
    Capital Expenditures$562.40M
    Free Cash Flow$867.20M
    FCF Per Share$20.22
    Depreciation and Amortization$96.00M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 41.45%, against a 5-year average of 45.85%.

    Gross Margin86.34%
    Operating Margin41.45%
    Pretax Margin47.30%
    Net Margin38.61%
    FCF Margin27.21%
    Gross Margin (5Y Average)90.20%
    Operating Margin (5Y Average)45.85%
    Net Margin (5Y Average)38.31%

    Growth

    Revenue grew 18.02% a year over 3 years, and EPS 20.19% a year.

    Revenue Growth (3Y CAGR)+18.02%
    Revenue Growth (5Y CAGR)+16.50%
    EPS Growth (3Y CAGR)+20.19%
    EPS Growth (5Y CAGR)+15.87%
    FCF Growth (3Y CAGR)+16.18%
    FCF Growth (5Y CAGR)+8.37%
    Operating Income Growth (3Y CAGR)+15.06%
    Book Value Per Share Growth (2Y CAGR)+11.03%
    Tangible Book Per Share Growth (2Y CAGR)+11.18%

    Revenue and profit by year

    Dividends and Yields

    UTHR does not pay a dividend. Its free cash flow yield is 3.48%.

    Earnings Yield4.55%
    FCF Yield3.48%
    Buyback Yield7.98%
    Shareholder Yield7.98%

    Stock Splits

    The last split was a 2-for-1 forward split on Sep 23, 2009.

    Last Split DateSep 23, 2009
    Split TypeForward split
    Split Ratio2:1

    Peer Position

    Against 9 similar companies, UTHR has the 4th highest P/E.

    P/E Ratio22.0x vs 18.5x median
    P/S Ratio7.8x vs 2.9x median
    Revenue Growth (Trailing 4 Quarters, YoY)+1.89% vs +5.73% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 6.41% and EPS growth at 6.16% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+6.41%
    EPS Growth Forecast (2Y CAGR)+6.16%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About UTHR

    What is UTHR's market cap?

    United Therapeutics has a market cap of $25.04B. Its enterprise value, which adds debt and subtracts cash, is $23.85B.

    What is UTHR's P/E ratio?

    United Therapeutics has a trailing P/E ratio of 22.0x and a forward P/E of 21.8x.

    How many shares of UTHR are outstanding?

    United Therapeutics has 42.70M shares outstanding. The count is down 2.51% from a year earlier.

    Does UTHR pay a dividend?

    No. United Therapeutics does not pay a dividend.

    How much debt does UTHR have?

    United Therapeutics has $0 of total debt and $1.19B of cash and equivalents, a net cash position of $1.19B.